rs2233434 — NFKBIE

Missense variant in NFKBIE (IκBε) reducing the inhibitory capacity of the IκB-epsilon protein, leading to heightened NF-κB inflammatory signaling; the G allele is associated with rheumatoid arthritis susceptibility across multiple ancestries

See your personal result for NFKBIE

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NFKBIE Val55Ala — An IκBε Brake Failure in the NF-κB Inflammatory Circuit

Rheumatoid arthritis (RA) is driven by the chronic overactivation of NF-κB11 NF-κB
Nuclear factor kappa-B — a master transcription factor that controls genes for TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines; it is normally held inactive in the cytoplasm by a family of inhibitor proteins called IκBs, the master inflammatory transcription factor. The gene NFKBIE encodes IκBε (IκB-epsilon)22 IκBε (IκB-epsilon)
Inhibitor of kappa-B epsilon — a member of the IκB family that binds primarily to RELA (p65) and REL NF-κB subunits, sequestering them in the cytoplasm and preventing inflammatory gene transcription; IκBε contains six closely spaced ankyrin repeats and operates more slowly than IκBα, acting as a late-phase dampener of NF-κB oscillations, one of the key brake proteins that normally keeps NF-κB restrained. The rs2233434 variant introduces a valine-to-alanine substitution at position 55 (p.Val55Ala in current transcript nomenclature; Val194Ala in older transcript annotations), which impairs the ability of IκBε to suppress NF-κB activity. In a landmark genome-wide association study, this G-allele variant emerged as one of the most significant non-HLA RA susceptibility loci identified to date.

The Mechanism

IκBε normally binds RELA and REL NF-κB subunits in the cytoplasm through its six ankyrin repeats, preventing them from entering the nucleus and activating inflammatory gene transcription. When cells are stimulated with pro-inflammatory signals (TNF-α, LPS, or antigen receptor engagement), IKK kinases phosphorylate IκBε, targeting it for proteasomal degradation and releasing NF-κB to translocate to the nucleus. Unlike the rapidly recycled IκBα, IκBε operates on a slower timescale and is responsible for dampening the late phase of NF-κB activation — functioning as an oscillation dampener that prevents sustained chronic inflammatory signaling.

The Val55Ala substitution is located in the ankyrin repeat domain of IκBε. Functional assays by Myouzen et al.33 Functional assays by Myouzen et al.
Myouzen et al. 2012 — transfected HEK293 cells with risk (G-T) versus non-risk (A-C) haplotype constructs and measured NF-κB activity by luciferase reporter; the risk haplotype showed higher NF-κB transactivation and lower allelic transcript abundance, consistent with reduced inhibitory capacity demonstrated that the risk haplotype carrying the G allele of rs2233434 shows higher NF-κB activity compared to the non-risk haplotype, along with slightly lower transcript abundance — together suggesting that this variant both reduces the amount of IκBε protein and impairs the inhibitory function of whatever IκBε is produced. The net result is a leaky NF-κB brake: inflammatory stimuli activate NF-κB more easily, and the inflammatory signal lingers longer before being extinguished.

The Evidence

The primary discovery came from a large GWAS and two-stage replication in the Japanese population44 large GWAS and two-stage replication in the Japanese population
Myouzen et al. 2012, PLoS Genetics — Japanese GWAS (stage 1) plus two independent replication cohorts; 7,907 RA cases and 35,362 controls total; rs2233434 reached genome-wide significance at OR=1.20, 95% CI 1.15–1.26, p=1.3×10⁻¹⁵. This established NFKBIE as the second-largest non-HLA RA risk locus at the time of discovery.

The association has since been replicated across multiple ancestries. Trans-ethnic meta-analysis55 Trans-ethnic meta-analysis
Identified NFKBIE as having strong cross-population support: OR_EUR=1.25, OR_EAS=1.24, OR_AA=1.50, with a combined trans-ethnic p=1.57×10⁻¹⁹; the variant was identified as approximately 400 times more likely than the neighboring rs2233433 to be the pathogenic variant at this locus, with a posterior probability of pathogenicity of 0.482 confirmed that the effect is consistent in European (OR=1.25) and African American populations (OR=1.50), with the latter showing a notably larger effect size despite the G allele being rarer in African populations (~6%). These consistent trans-ethnic effects support a genuine biological role for this variant rather than a population-specific linkage artifact.

Beyond RA, a separate line of evidence connects this variant to drug response. Hashizume et al. 201666 Hashizume et al. 2016
Hashizume et al., Modern Rheumatology 2016 — overexpression of Val194Ala (rs2233434) mutant NFKBIE in human RA synovial fibroblasts (MH7A) showed reduced SLC19A1 mRNA compared to wild-type NFKBIE overexpression, particularly at methotrexate concentrations above 5 μM; methotrexate-polyglutamate accumulation was also reduced showed that the Val194Ala variant reduces expression of SLC19A1, the primary membrane transporter responsible for methotrexate uptake into cells. This creates a potential double vulnerability for G-allele carriers: higher baseline inflammatory signaling driving RA development, and potentially reduced efficacy of the first-line RA treatment methotrexate.

The risk allele frequency shows marked population stratification: G is found at approximately 18% in East Asian populations compared to only 4% in Europeans and 2% in South Asians. This higher frequency in East Asia may contribute to observed differences in RA prevalence and presentation across ancestries.

Practical Actions

For G-allele carriers, the most clinically relevant implication concerns awareness of RA risk markers and proactive monitoring. RA develops in predisposed individuals when genetic susceptibility combines with environmental triggers — smoking, periodontal disease, infections, and hormonal transitions. Early joint inflammation treated before significant cartilage erosion occurs preserves function dramatically better than late intervention.

The SLC19A1 connection also has practical implications: if G-allele carriers with RA are prescribed methotrexate and show inadequate response at standard doses, the NFKBIE variant may contribute to reduced drug uptake. Awareness of this pharmacogenomic dimension can guide earlier escalation to biological therapies when needed.

Interactions

NFKBIE functions within the canonical NF-κB pathway upstream of STAT4 (rs7574865). IκBε controls whether NF-κB enters the nucleus to produce IL-12 and IL-23 — the cytokines that STAT4 senses to drive Th1 polarization. Individuals carrying the NFKBIE G allele (more NF-κB activity, more IL-12/IL-23 production) together with the STAT4 T allele (higher IL-12/IL-23 sensitivity) may have amplified Th1 polarization relevant to both RA and other autoimmune conditions. This interaction has not been formally characterized for RA, but parallels the well-studied NFKBIE × STAT4 genetic architecture in SLE.

rs2233433 is a neighboring nsSNP in NFKBIE (Pro175Leu on older transcript numbering) that was studied in haplotype context with rs2233434 in the Myouzen et al. paper; the two form a risk haplotype (G-T) where both contribute to enhanced NF-κB activity. The rs41298997 IKBKE variant is in a different gene (IKKε kinase) but shares the NF-κB signaling axis; compound risk at both loci could amplify inflammatory signaling through both the inhibitor (NFKBIE) and kinase (IKBKE) arms of the pathway.

Drug Interactions

methotrexate reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Full IκBε function — standard NF-κB inflammatory signaling

You carry two copies of the A (reference) allele at rs2233434 in the NFKBIE gene. This is the common genotype in most populations (approximately 83% globally, and ~92% in European populations). Your IκBε protein carries the standard valine at position 55, preserving the inhibitory function that keeps NF-κB appropriately restrained between inflammatory stimuli. This genotype is not associated with elevated RA risk from this specific locus.

AG Intermediate

One copy of the NFKBIE risk allele — modestly reduced IκBε inhibitory capacity

The G allele introduces a valine-to-alanine change at position 55 of IκBε, which sits in the ankyrin repeat domain responsible for NF-κB binding. Luciferase reporter assays showed the risk haplotype carrying this change produces higher NF-κB transcriptional activity than the non-risk haplotype. The variant also associates with ~10–20% lower NFKBIE transcript levels, compounding the functional deficit.

An important downstream consequence: the Val55Ala variant reduces expression of SLC19A1, the membrane transporter that imports methotrexate into cells. This is relevant if RA develops and methotrexate is used as first-line therapy — reduced transporter expression may blunt methotrexate uptake and contribute to treatment resistance.

RA develops at the intersection of genetic susceptibility and environmental triggers. Key triggers to minimize: smoking (substantially increases RA risk and accelerates joint damage in established disease), periodontal disease (shares pathogenic mechanisms with RA), and untreated bacterial infections. Anti-CCP and RF antibodies typically appear years before clinical joint disease — monitoring these biomarkers provides early-warning capability.

GG High Risk

Two copies of the NFKBIE risk allele — maximal IκBε impairment at this locus

Both copies of NFKBIE carry the Val55Ala substitution, meaning all IκBε protein produced in your cells carries the impaired ankyrin-repeat variant. Functional data show this correlates with higher NF-κB transcriptional activity and lower NFKBIE transcript levels than non-risk genotypes. Sustained NF-κB hyperactivation in immune cells drives production of TNF-α, IL-1β, IL-6, and IL-17 — the cytokines responsible for synovial inflammation, pannus formation, and cartilage erosion in RA.

The SLC19A1 pharmacogenomic consequence is also maximal here: with both alleles carrying Val55Ala, baseline SLC19A1 expression may be substantially lower than in AA carriers, increasing the probability of inadequate methotrexate response if RA is treated with standard first-line therapy.

GG homozygotes benefit from proactive surveillance and early treatment initiation. Disease-modifying antirheumatic drugs (DMARDs), particularly biologics targeting TNF-α, IL-6 (tocilizumab), or JAK/STAT (tofacitinib, baricitinib), directly address the downstream consequences of the elevated NF-κB signaling this genotype promotes. Anti-CCP antibodies often precede clinical joint disease by years; a positive result is an indication for rheumatology referral even without overt synovitis.